These findings may explain the results of the CRC patients in the phase 1 study for SLC-0111, in which only one of the enrolled CRC patients showed a period of stable disease upon treatment with SLC-0111 [48], which could be due to a tumor with high expression of CAIX and CAXII, most probably a CMS3 tumor. The gene discussed is CA12; the disease is neoplasm.